Global /South Korea /Healthcare /Drug Manufacturers - General /009300

Sam-A Pharm. Co., Ltd.

009300

• KRX: 009300 • Delayed

16,370KRW 0.1%

10.78 USD

As of 16 June 2026, Sam-A Pharm. Co., Ltd. has a market cap of $65.97M USD, ranking #28574 globally and #1533 in South Korea. It ranks #2588 in the Healthcare sector, and #923 in the Drug Manufacturers - General industry.

Global Rank

28574

Country Rank

1533

Sector Rank

2588

Industry Rank

923

Key Stats

Market Cap

$65.97MUSD

99.91B KRW

Enterprise Value

$6.07MUSD

9.21B KRW

Revenue (TTM)

$51.37MUSD

77.8B KRW

EBITDA (TTM)

$10.4MUSD

15.79B KRW

Net Income (TTM)

$8.54MUSD

12.94B KRW

EBITDA Margin

20%

Profit Margin

17%

PE Ratio

7.7

PS Ratio

1.3

PB Ratio

0.4

EV/EBITDA

0.6

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Heo Jun open_in_new

Employees

300

Founded

1945

Website

samapharm.co.kr open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.1%	1.1%	2.7%	3.2%	-2.8%	4.2%	-3.4%	2.4%	2.3%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	009300 삼아제약(주) ISIN: KR7009300005 Shares Out.: Shares Outstanding: 6.103M¹ Shares Float: 1.841M² TV: TradingView: KRX: 009300 SA: Stock Analysis: KRX: 009300 YF: Yahoo Finance: 009300.KS GF: Google Finance: KRX: 009300 BA: Barron's: 009300 MS: Morningstar: XKRX: 009300	16,370 KRW	TV: TradingView: KRX: 009300 SA: Stock Analysis: KRX: 009300 YF: Yahoo Finance: 009300.KS GF: Google Finance: KRX: 009300 BA: Barron's: 009300 MS: Morningstar: XKRX: 009300

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Sam-A Pharm. Co., Ltd.

Sam-A Pharm. Co., Ltd operates as a pharmaceutical company in South Korea. The company offers a range of pharmaceutical products in the areas of respiratory, antibiotics, anti-virals, anti-histamines, anti-fungals, dermatology, pain/inflammation, gastrointestinal, cardiovascular, metabolism, urological, and steroids, as well as psychotropic agents; and OTC products in the areas of respiratory, ant-analgesics, gastro-intestinal, topical, oral, and anti-histamines. It provides NOMA MEGAFFECT for stress relief, eye care, memory and blood lipid concentration enhancement, endurance enhancement, and the supply of vitamins and minerals; and NOMA-F gummy, NOMA CHEWABLE tablet, and NOMA GOLD chewable tablet for growth promotion, enhancement of nutritional deficiency, and supply of vitamins. The company was founded in 1945 and is based in Seoul, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Epis Holdings Co., Ltd. KRX: 0126Z0	$9.18B 13.91T KRW 14K%	-	South Korea
Sam Chun Dang Pharm. Co., Ltd. KRX: 000250	$6.8B 10.3T KRW 10K%	1958.1	South Korea
SK Biopharmaceuticals Co., Ltd. KRX: 326030	$5.26B 7.97T KRW 8K%	29.9	South Korea
ABL Bio Inc. KRX: 298380	$4.98B 7.55T KRW 7K%	-	South Korea
Yuhan Corp. KRX: 000100	$4.57B 6.92T KRW 7K%	35.9	South Korea
LigaChem Biosciences Inc. KRX: 141080	$4.46B 6.76T KRW 7K%	-	South Korea

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 1M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 830K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 547K%	97.4	United States
Roche Holding AG SIX: RO	$320.51B 256.25B CHF 486K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.14B 215.59B GBP 437K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 415K%	15.1	United States

chevron_leftBack